What new medications can be used to treat nighttime restlessness and anxiety?

New Medications for Nighttime Restlessness and Anxiety

For nighttime restlessness and anxiety, the newest FDA-approved medication class is the dual orexin receptor antagonists (DORAs), with daridorexant being the most recent addition (2022), offering an 8-hour half-life and demonstrated 12-month efficacy without rebound insomnia or abuse potential. 1

First-Line Pharmacological Approach

When pharmacotherapy is indicated for nighttime restlessness and anxiety manifesting as insomnia, follow this algorithmic sequence:

Newer Agents (2017-Present)

Orexin Receptor Antagonists (DORAs):

• Suvorexant (10-20 mg): Specifically targets sleep maintenance insomnia by inhibiting wakefulness rather than inducing sedation 2
• Daridorexant: The newest DORA with optimal 8-hour half-life, no rebound insomnia, no withdrawal symptoms, and minimal abuse potential 1
• Lemborexant: Alternative DORA option with similar mechanism

Key advantage: Unlike benzodiazepines and older agents, DORAs work by blocking wake-promoting orexin signaling rather than forcing sedation, resulting in more physiologic sleep architecture 1

Established First-Line Options

If DORAs are unavailable or unsuitable:

Benzodiazepine Receptor Agonists (BzRAs):

• Eszopiclone (2-3 mg): Treats both sleep onset and maintenance 2
• Zolpidem (10 mg): Treats both sleep onset and maintenance 2
• Zaleplon (10 mg): Specifically for sleep onset 2

Melatonin Receptor Agonist:

• Ramelteon (8 mg): For sleep onset insomnia, works on circadian rhythm 2

Low-Dose Tricyclic:

• Doxepin (3-6 mg): Specifically for sleep maintenance insomnia 2

Critical Considerations for Anxiety Component

When anxiety is the primary driver of nighttime restlessness:

Avoid these despite common off-label use:

• Trazodone (50 mg): Guidelines explicitly recommend AGAINST use for insomnia 2
• Diphenhydramine: Not recommended due to lack of efficacy and safety data 2
• Melatonin (OTC): Not recommended for chronic insomnia 2
• Tiagabine: Explicitly not recommended 2

If comorbid anxiety disorder exists:

• Consider sedating antidepressants as second-line: mirtazapine (also helps anorexia), low-dose doxepin 3
• SSRIs/SNRIs for daytime anxiety treatment, combined with appropriate sleep medication 4, 5

Special Populations

Older Adults:

• Start with lowest doses
• Avoid benzodiazepines (clonazepam, temazepam, triazolam) due to cognitive impairment risk and Beers Criteria listing 6, 7
• Prefer DORAs or ramelteon due to better safety profile
• Reduce zolpidem to 5 mg (from 10 mg) per FDA requirements 8

Palliative Care/Cancer Patients:

• For refractory insomnia: lorazepam, zolpidem, or mirtazapine (especially with depression/anorexia) 8
• Quetiapine or olanzapine for severe cases
• Avoid benzodiazepines in cognitively impaired patients 8

Critical Safety Warnings

All BzRAs carry FDA warnings for:

• Sleep-related complex behaviors (sleepwalking, sleep-driving, sleep-eating)
• Must allow adequate sleep time (7-8 hours)
• Avoid alcohol and other CNS depressants
• Use prescribed doses only 3

Benzodiazepines specifically:

• Risk of dependence and withdrawal
• Rebound insomnia on discontinuation
• Should be lowest effective dose with tapering when possible 3

Treatment Algorithm

1. Rule out secondary causes: Iron deficiency, medications, other sleep disorders (sleep apnea, restless legs syndrome) 6, 9

2. First attempt: Cognitive behavioral therapy for insomnia (CBT-I) - most effective long-term 3

3. If pharmacotherapy needed:

   • First choice: DORA (daridorexant, suvorexant, lemborexant)
   • Alternative first-line: Eszopiclone, zolpidem, or ramelteon based on symptom pattern
   • Second-line: Low-dose doxepin for maintenance insomnia
   • Third-line: Combination therapy or sedating antidepressants if comorbid depression/anxiety

4. Follow-up: Every few weeks initially to assess effectiveness and side effects 3

5. Long-term management: Use lowest effective dose, attempt tapering when conditions allow, continue CBT-I during pharmacotherapy 3

Common Pitfalls to Avoid

• Do not use trazodone despite its popularity - guidelines explicitly recommend against it 2
• Do not prescribe OTC antihistamines or melatonin for chronic insomnia 3, 2
• Do not use benzodiazepines as first-line in older adults 6, 7
• Do not combine with alcohol or use without adequate sleep opportunity 3
• Do not assume insomnia is secondary - treat as distinct disorder even with comorbid conditions 3, 1